FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients

BACKGROUND: The objective of this prospectively randomized phase II trial (Trial registration: EUCTR2004-004007-37-DE) was to compare the clinical response of primary breast cancer patients to neoadjuvant therapy with letrozole alone (LET) or letrozole and zoledronic acid (LET + ZOL). METHODS: Patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Fasching, Peter A, Jud, Sebastian M, Hauschild, Maik, Kümmel, Sherko, Schütte, Martin, Warm, Matthias, Hanf, Volker, Grab, Dieter, Krocker, Jutta, Stickeler, Elmar, Kreienberg, Rolf, Müller, Thomas, Kühn, Thorsten, Wolf, Christopher, Kahlert, Steffen, Paepke, Stefan, Berghorn, Michael, Muth, Mathias, Baier, Monika, Wackwitz, Birgit, Schulz-Wendtland, Rüdiger, Beckmann, Matthias W, Lux, Michael P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3937056/
https://www.ncbi.nlm.nih.gov/pubmed/24499441
http://dx.doi.org/10.1186/1471-2407-14-66

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3937056/
https://www.ncbi.nlm.nih.gov/pubmed/24499441
http://dx.doi.org/10.1186/1471-2407-14-66

Ejemplares similares